-transparent.png){kind=logo}
Adverse alterations in lipid profile suggesting higher atherogenicity were observed following 12 weeks treatment with atenolol in patients of hypertension. No significant alterations in lipid profile were observed with labetalol therapy.
Related Publications
S B Siwach, and
S S Dahiya, and
S Seth, and
R K Seth, and
D Sharma
January 1987,
Nephron,
S B Siwach, and
S S Dahiya, and
S Seth, and
R K Seth, and
D Sharma
September 2002,
Zeitschrift fur Kardiologie,
S B Siwach, and
S S Dahiya, and
S Seth, and
R K Seth, and
D Sharma
January 1981,
Lancet (London, England),
S B Siwach, and
S S Dahiya, and
S Seth, and
R K Seth, and
D Sharma
November 1996,
Blood pressure,
S B Siwach, and
S S Dahiya, and
S Seth, and
R K Seth, and
D Sharma
September 1981,
South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde,
S B Siwach, and
S S Dahiya, and
S Seth, and
R K Seth, and
D Sharma
January 1991,
Journal of cardiovascular pharmacology,
S B Siwach, and
S S Dahiya, and
S Seth, and
R K Seth, and
D Sharma
June 1991,
Journal of human hypertension,
S B Siwach, and
S S Dahiya, and
S Seth, and
R K Seth, and
D Sharma
January 1982,
Journal of cardiovascular pharmacology,
S B Siwach, and
S S Dahiya, and
S Seth, and
R K Seth, and
D Sharma
January 1988,
Ancient science of life,
S B Siwach, and
S S Dahiya, and
S Seth, and
R K Seth, and
D Sharma
August 1973,
The New England journal of medicine,
